MGC Pharma (ASX:MXC) share price jumps 11% on UK approval

This cannabis share is smoking the market today…

| More on:
Cannabis from the earth in the hands

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The MGC Pharmaceuticals Ltd (ASX: MXC) share price is charging higher on Tuesday.

In early trade, the cannabis company's shares are up 11.5% to 6.7 cents.

Why is the MGC Pharma share price charging higher?

Investors have been bidding the MGC Pharma share price higher on Tuesday following the release of a positive update on its UK operations.

According to the release, the company's CannEpil+ product has been approved for UK import and prescription by the Medicine and Healthcare products Regulatory Agency (MHRA).

CannEpil+ is a biosimilar effect-identical product of CannEpil, which is a phytocannabinoid treatment for drug-resistant epilepsy. The release notes that the approval was facilitated by its UK distribution and clinical access partner, Elite Pharmaco.

It notes that this will be the first time that UK authorities have approved an epilepsy treatment that is on a clinical pathway containing THC. This is in response to the urgent need of some patients to have access to a clinical product which has demonstrated its efficacy at treating drug-resistant epilepsy.

CannEpil+ will initially be used to treat ten patients in the UK who suffer from drug-resistant epilepsy. MGC Pharma will be providing CannEpil+ free of charge to these patients on compassionate grounds for six months.

Management commentary

MGC Pharma's Co-Founder and Managing Director, Roby Zomer, commented: "The approval for the import of CannEpil+ to the UK and the associated compassionate prescriptions is an important step towards our global roll out of the treatment, and our continued commitment to patients. Achieving MHRA approval has been an ongoing process for some time with our UK partner Elite Pharmaco, and we expect the first patients in the UK to begin treat with CannEpil+ in the coming months."

"The development of our Data Collection App will optimise our understanding of both CannEpil, CannEpil+ and other future treatments, and ultimately provide patients with a better treatment for Refractory Epilepsy, and therefore improving their quality of life. It is also a vitally important foundation for building strong relationships with UK medical regulators and health organisations which will benefit MGC Pharma going forward, as we look to roll out further clinical trials and products in the UK," he added.

The MGC Pharma share price is now up over 200% in 2021.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a strong start to the trading week for the ASX 200 this Monday.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Why GenusPlus, NIB, Superloop, and Titomic shares are racing higher today

These shares are starting the week on a positive note. But why?

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Up 99% in a year, guess which ASX 300 stock is rocketing higher again today

Investor are piling into the $1.6 billion ASX 300 company again today. But why?

Read more »

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing end to the trading week for investors this Friday.

Read more »

A young boy points and smiles as he eats fried chicken.
Share Gainers

3 ASX All Ords shares smashing the benchmark this week

Investors are sending these three ASX All Ords shares rocketing 18% to more than 29% this week. But why?

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why Alliance Aviation, BHP, Boss Energy, and Orthocell shares are racing higher

These shares are ending the week on a positive note. But why?

Read more »

Man with backpack spreading his arms out and soaking in the sun.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing session for investors today.

Read more »

Hands reaching high for a trophy with a sunset in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a nervous hump day session for ASX investors today.

Read more »